FinanceCMS Proposes Rule to Base Prescription Drug Payments on Patient Outcomes
CMS stated that the proposed rule will also bolster the agency's efforts to combat the opioid epidemic.
Clinical CareManaging Medication Adherence During COVID-19
Coronavirus fears drive medication adherence ups and downs.
Clinical CareMedicare Part D Model Caps Insulin Copays at $35 a Month
Beneficiaries who use insulin and join a plan participating in the voluntary model, beginning January 2021, could see average out-of-pocket...
StrategyWhat We Know — and Don't Know — About Possible Coronavirus Treatments Promoted by Trump
There isn?t enough evidence that decades-old anti-malarial drugs work for the treatment or prevention of coronavirus, but here?s what we...
StrategyGilead Backtracks on Orphan Drug Designation for Remdesivir
NIH is testing the antiviral drug's safety and efficacy against COVID-19.
StrategyDoctors Are Hoarding Unproven Coronavirus Medicine by Writing Prescriptions for Themselves and Their Families
Demand for chloroquine and hydroxychloroquine surged over the past several days as President Donald Trump promoted them as possible treatments...
FinanceAllergan Reduces Operating Loss by 29%, Revenues Tick Up
The Dublin-based drugmaker improved on most financial metrics during 2019.
StrategyCMS Proposes 0.93% Pay Rate Hike for MA Plans in 2021
The rate hike is part of a broader package of proposed "refinements" for Medicare Advantage and the Part D Quality...
FinanceBristol-Myers Squibb Revenues Top $26B, EPS Falls 33%
The New York-based drugmaker also saw U.S. revenues rise 42% in Q4 2019.
FinanceWorldwide Sales for Merck Nearly Reach $47B
The Kenilworth, New Jersey?based drugmaker also announced plans to spin off three segments into a new company.
FinancePfizer Revenues Slide to End 2019
The New York-based drugmaker projects its 2020 revenues will be between $48.5 billion to $50.5 billion.
FinanceFTC, NY AG Charge 'Pharma Bro' Martin Shkreli and Vyera Pharmaceuticals in Daraprim Price Scheme
Martin Shkreli, nicknamed the 'pharma bro,' was sentenced to seven years in prison for securities fraud in 2018.